Literature DB >> 14595171

Adolescent idiopathic scoliosis: case report with 63-year follow-up postsurgery.

Robert B Winter1, John E Lonstein.   

Abstract

STUDY
DESIGN: Retrospective case report.
PURPOSE: To provide true outcome analysis by a 63-year follow-up.
MATERIAL AND METHODS: A 16-year-old girl had a posterior spine fusion for adolescent idiopathic scoliosis in 1939 and has been followed ever since. Both original photographs and radiographs as well as current material are available. BACKGROUND INFORMATION: A follow-up of this duration has not previously been reported.
RESULTS: She had a solid T9-L3 arthrodesis and had no problems until age 50 when degenerative changes at L3-L4 required extension of the fusion to L4. When seen in 2002 at age 79, she had problems with degenerative disc disease at L4-S1 with spinal stenosis symptoms.
CONCLUSIONS: The original fusion area remained solid and without symptoms for 63 years. Distal degenerative changes began 34 years after her original surgery and are still present at the 63-year follow-up. These degenerative changes at L4-L5 and L5-S1 are often thought to be secondary to the arthrodesis to L4, but because they are extremely common in persons of this age who do not have scoliosis or a fusion mass to L4, it is not possible to imply a cause and effect relationship. True outcome results cannot be ascertained at a 2-year or even 10-year follow-up.

Entities:  

Mesh:

Year:  2003        PMID: 14595171     DOI: 10.1097/01.BRS.0000096461.08464.A9

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  2 in total

1.  Scoliosis in adulthood-a case with untreated early onset scoliosis presenting at the age of 76 years.

Authors:  Hans-Rudolf Weiss
Journal:  J Phys Ther Sci       Date:  2016-12-27

2.  Ultra-long-term follow-up of pediatric spinal deformity problems: 23 patients with a mean follow-up of 51 years.

Authors:  Robert B Winter; John E Lonstein
Journal:  J Orthop Sci       Date:  2009-04-01       Impact factor: 1.601

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.